FirstWord: Market Research Reports

... uptake in stage III melanoma? How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma? Update Bulletins include expert ... valuable insights with each update. Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers ...

... that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; ... Merck’s Keytruda as a second-line treatment for PD-L1 positive advanced NSCLC? Update Bulletins include expert insight and analysis based on FirstWord ...

... and market access functions, what role can – or should - marketing play in the future? Pharma Marketing 2020: Drivers of change analyses the operational challenges marketers face and examines solutions that will underpin solid, integrated marketing ...

Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): the future of inhaled insulin in the light of the licensing ... ’s biosimilar insulin glargine (Basaglar/Abasaglar). Key Questions Answered in this Update Bulletin: What do KOLs think about the future of inhaled insulin ...

... Update Bulletin: Will safety concerns related to anti-IL-17 mAbs influence physician adoption of Eli Lilly’s ixekizumab as a treatment for moderate to severe plaque psoriasis? Following ... as treatments for moderate to severe plaque psoriasis, and which programmes are KOLs most excited about? Update Bulletins include expert insight and analysis ...

... latest measurement and evaluation techniques? MSL Metrics: Measuring Success is essential reading for MSL managers and practitioners. The report is based on the insight and experience of 9 MSL professionals ... . What key MSL metrics aren’t you measuring? What type of training can elevate MSL success to new levels? What are the essential metrics of MSL assessment and how ...

... ’s NPS+ Multiple Sclerosis (EU5) report answers these and other important questions for brands used to treat MS Building on the highly respected Net Promoter Score (NPS ... concern. What is it? Get answers to key questions about brand loyalty NPS+ Multiple Sclerosis (EU5) explores key issues affecting brand loyalty for MS drug makers ...

... ’s NPS+ Multiple Sclerosis (US) report answers these and other important questions for brands used to treat MS. Building on the highly respected Net Promoter Score (NPS ... concern. What is it? Get answers to key questions about brand loyalty NPS+ Multiple Sclerosis (US) explores key issues affecting brand loyalty for MS drug makers ...

... Benefits Understand the Unique Benefits of KOL Insight: Prostate cancer Prostate Cancer: Competition intensifies in race to the top examines the most prominent insights gained from the field’s key ... performance of companies with the most robust new product pipelines Prostate Cancer: Competition intensifies in race to the top answers key questions including: How ...

Malignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatment combination choices ... view of this vaccine. Does it have any future as a malignant melanoma treatment? Seviprotimut-L (POL 103A): KOLs are still asking big questions about this ...

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

... -in-class multichannel operators in other sectors? How well is data being used to inform and improve multichannel marketing efforts? What are the barriers to better multichannel marketing ... , Multichannel & Digital, Top 10 pharma company Head of Digital Acceleration, Emerging Markets, Top 10 pharma company Consultant and former Executive Director of Strategy, Global Commercial Excellence ...

... need Drug Delivery - Innovations, trends, and their impact on pharma Revolutionary changes are disrupting the status quo simply through developments in the way drugs are ... on innovation in the drug delivery market, reimbursement concerns and access issues Who needs this report? Presidents and VPs of product development – to see the drugs ...

... the value story of your products before taking them to the market. Get Market Access Value Stories: Developing effective messages and communications with payers now. Top Takeaways Develop your ... importance of developing and communicating strong value stories Market access advisers and consultants – as more pharma companies turn to specialists for advice, is your understanding of value propositions sufficient ...

... rheumatoid arthritis Medical Affairs team leading the pack or following behind?  How well are the Medical Affairs teams from biosimilar manufacturers performing when ... needs, or is there still room for improvement? See where your EU5 Medical Affairs team comes in the latest ranking, together with insights into ...

... your rheumatoid arthritis Medical Affairs team leading the pack or following on behind? How are Medical Affairs teams from challenger brands shaping up when compared with ... competing treatments Key issues explored How physicians rate your rheumatoid arthritis Medical Affairs team Interaction quality, performance and satisfaction measured and ...

... improvement: In the areas of high importance EU5 teams fail to perform as well as the US equivalents. Reputations vary considerably: Top team ... Key issues explored How the reputations of the medical affairs teams specialising in Asthma/COPD are evaluated How medical affairs teams are being used by physicians ...

... for market share? Prostate Cancer: KOL Insight looks at the future of prostate cancer therapy and provides insight from 12 leading North American and European KOLs. How will marketed ... co-administration a competitive disadvantage? And could it play a role in metastatic hormone-naïve prostate cancer? Pipeline Therapies Apalutamide (JNJ-927/ARN-509; Johnson & Johnson ...

... role in training MSLs and commercial staff to ensure consistent and evidence-based product messaging? Post launch involvement: The broadening role of medical affairs after launch is becoming critical. Where, how and why? Market Access: What are the arguments for medical affairs taking a wider role ...

... Multiple Sclerosis Unit in the Healthcare Complex of Avila, Spain. Anonymous, German KOL, is a Professor of Neurology. This expert is Managing Lead Consultant of a neurology Anonymous, European KOL ...

... cancer immunotherapies. Payers believe that pharma companies do not properly appreciate their budget limitations. Reducing the costs of immunotherapy ...

... standard operating procedures are needed for Phase IV studies Planning should start earlier for Phase IV studies to improve their effectiveness and business ... needs this report? Anyone involved in designing, recruiting, executing or analysing Phase IV studies – to see how they can be improved Regulatory teams – to gain ...

... be evaluated? Prepare now to best leverage this critical function tomorrow. Order Tomorrow’s MSLs to find out how. Benefit from the experience and expertise ... can you add the value.” MSL, Eisai EMEA, EU Top Takeaways The key is adding value: Tomorrow’s MSLs will have the competitive edge ... categories changes on a daily basis. The new skill set required of tomorrow’s MSLs includes integrity, technical and analytical expertise, an understanding of the pharmaceutical ...

... Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs ... your Medical Affairs team versus your competitors? Where is your Medical Affairs team succeeding and where are there opportunities for improvement? Emerging Themes: Medical Affairs ...

... of U.S. Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs ... your Medical Affairs team versus your competitors? Where is your Medical Affairs team succeeding and where are there opportunities for improvement? Emerging Themes: Medical Affairs ...

... of sales reps on the street and directing them to pursue prescribing physicians. But what is the new model? Reshaping the Pharma Sales Force: A blueprint for contemporary sales ... organising principle for pharma sales forces. Who needs this report Sales leaders who are ready to think differently about structuring their sales forces — and ready ...

... ’s communications innovations are making a real difference in medical information and communications? What feedback are companies getting from their constituents as they explore innovation in medical information and communications ... , compliant medical information and medical communications are important to your business, you need to read Innovations in Medical Information and Communication. About FirstWord Reports FirstWord is an innovative industry intelligence ...

... patient centricity” a passing fad? Experts say it’s here to stay. In fact, it’s been called a “strategic necessity.” Companies like Pfizer and Sanofi know it. Patient Centric Pharma gives you an insider’s look at how they and others are using patient centricity to build business and cement relationships, and ...

... regions. We asked neurologists who see patients with Multiple Sclerosis for their opinions on the Medical Affairs professionals they had dealt with in relation ... scientific and product information Which Medical Affairs teams are performing best and worst for the Multiple Sclerosis sector Methodology Sample Distribution ...

... regions. We asked neurologists who see patients with Multiple Sclerosis for their opinions on the Medical Affairs professionals they had dealt with in relation ... scientific and product information Which Medical Affairs teams are performing best and worst for the Multiple Sclerosis sector Methodology Sample Distribution ...

... MSL-KOL interaction are barriers that MSL directors and managers must overcome if they are to grow value in their MSL teams. FirstWord’s latest report, MSL-KOL Engagement: Optimal Reach and Response Under New Rules, provides the most current insight from leading subject experts familiar with the challenges MSLs ...

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the ... , including checkpoint inhibitors, vie for approval in this lucrative space. Non-Small Cell Lung Cancer: KOL Insight presents a comprehensive qualitative review of targeted therapies in the market ...

... , how can KAM meet the challenges that lie ahead? Trends and Innovations in Key Account Management provides anyone involved in developing, implementing or delivering ... for the implementation of a successful KAM programAbout FirstWord Reports FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and ...

... for new products? Type 2 Diabetes: KOL Insight is a comprehensive report that reveals the insights and opinions of 12 leading US and European KOLs. How they view ... KOL insights in Type 2 Diabetes: KOL Insight. Answers to Critical Questions SGLT-2 inhibitors look set to replace DPP-4 inhibitors in the second line add on setting: what do KOLs ...

... to deliver an experience patients will remember. Getting apps right is critical if Pharma is to successfully transform itself into a truly patient-centered business. Patient-centric Mobile Apps: Key Opportunities and Challenges for Pharma gives you the information you need to understand what patients, healthcare providers ...

... treatment of heart failure. Efficacy of the drug – and how it is viewed and utilised by physicians – will nevertheless come under scrutiny in light of its price ...

FDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – ... the drug, remarked analysts at Jefferies, questions remain as to whether Lundbeck and Otsuka can sufficiently differentiate Rexulti from these competitors. With Rexulti ...

... , suggest key opinion leaders. Supporting this view, prescription data indicate strong uptake of Ibrance since launch, discussion of which is likely to form a key ...

... reported studies of RVT-101. To gain better understanding about the views of doctors on the how recent events are shaping their perspective on AD as well ... approved over the next few years, describe your level of enthusiasm for prescribing an agent that offers a modest delay in cognitive decline ...

Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently interviewed by FirstWord. Novartis certainly appears confident in the commercial outlook for Cosentyx ...

... PD-1/PD-L1 inhibitors – in second-line, non-small-cell lung cancer (Physician Views Poll Results – Oncologists give thumbs up for Bristol-Myers Squibb's Opdivo despite ... 'translates' in Phase III studies, what level of usage would you expect for the atezolizumab plus chemotherapy combination in first-line NSCLC ...

... to whom exactly will physicians decide to prescribe Praluent and Repatha, and how will they decide ... injection. To gain better understanding about how the panel discussion has shaped their views on the two products, ... fellow anti-PCSK9 mAb, Repatha, particularly for doctors who are not comfortable with patients ...

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

... FDA is also expected to publish guidance on how generic versions of abuse deterrent opioids will be tested and marketed; providing a clearer view ... this week asking US-based primary care physicians the following questions… How ... of ADF opioids become available do you think they should be required by the FDA ...

... NASH resolution with no worsening of liver fibrosis. Indeed, Intercept shares have slumped more than 20 percent since the detailed plans were ... ? To gain better understanding about how the recent announcements from Intercept and Genfit are into physician’s evolving views on the various NASH agents, FirstWord ...

... approval of Opdivo in second-line squamous NSCLC – had supported this view and appeared to validate Bristol-Myers Squibb's status as a 'reluctant adopter ... priority review (based on data in PD-L1 positive patients, but with management taking up the potential for a broad label) and with Roche expected ...

... in MS Excel. Charting MSL Activity and Performance distils the key findings from one of the most comprehensive surveys of specialist Medical Science Liaison (MSL) personnel in the ... and experiences of 80 MSLs, this survey identifies critical variations in MSL activity and presents thought-provoking ideas for the improvement of MSL performance and assessment and ...

Clinical Trial Design for Commercial Success offers expert insights on how to best position drugs for success through strategic innovative design of clinical trials. Clinical trials make up, on average, nearly 60 percent ... , complacency in trial design and execution carries a heavy cost. From launch to patent expiry, Clinical Trial Design for Commercial Success offers key insights on building clinical trials that give ...

... market access issues you need to understand and practically address? Commercial Excellence in Rare Diseases and Orphan Drugs is a highly-detailed report for industry management ... orphan drugs and the way in which rare disease teams should be structured in order to maximise commercial success Understand the regulatory structures that determine ...

... for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first choice, and what future developments could unlock the market? Idiopathic Pulmonary Fibrosis: KOL Insight critically examines this therapeutic area through the expert insights of 12 leading US and European Key Opinion ...